$453 Million is the total value of Foresite Capital Management III, LLC's 24 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | $105,130,000 | -8.9% | 1,708,046 | 0.0% | 23.20% | -6.6% | |
| IMMU | Buy | Immunomedics, Inc. | $56,069,000 | -6.8% | 2,691,729 | +5.9% | 12.37% | -4.5% |
| ALDR | Alder BioPharmaceuticals, Inc. | $48,986,000 | +5.4% | 2,942,130 | 0.0% | 10.81% | +8.0% | |
| RCUS | Arcus Biosciences, Inc. | $48,030,000 | +13.9% | 3,445,461 | 0.0% | 10.60% | +16.7% | |
| MYOK | Sell | Myokardia, Inc. | $24,274,000 | +24.5% | 372,300 | -5.2% | 5.36% | +27.5% |
| AIMT | Sell | Aimmune Therapeutics, Inc. | $21,858,000 | -4.5% | 801,240 | -5.9% | 4.82% | -2.2% |
| CBAY | CymaBay Therapeutics, Inc. | $17,307,000 | -17.4% | 1,562,040 | 0.0% | 3.82% | -15.4% | |
| BPMC | Sell | Blueprint Medicines Corporation | $15,612,000 | -1.6% | 200,000 | -20.0% | 3.44% | +0.8% |
| XLRN | Sell | Acceleron Pharma Inc. | $14,357,000 | +6.2% | 250,863 | -10.0% | 3.17% | +8.8% |
| ASND | Ascendis Pharma A/Ssponsored adr | $13,576,000 | +6.5% | 191,588 | 0.0% | 3.00% | +9.1% | |
| REPL | New | Replimune Group, Inc. | $12,552,000 | – | 779,656 | +100.0% | 2.77% | – |
| BOLD | Audentes Therapeutics, Inc. | $12,484,000 | +3.6% | 315,331 | 0.0% | 2.76% | +6.2% | |
| SLDB | Sell | Solid Biosciences Inc. | $11,223,000 | -6.8% | 237,884 | -29.6% | 2.48% | -4.5% |
| EPZM | Sell | Epizyme, Inc. | $9,728,000 | -23.7% | 917,715 | -2.4% | 2.15% | -21.8% |
| AKAOQ | Sell | Achaogen, Inc. | $9,474,000 | -61.9% | 2,374,418 | -17.4% | 2.09% | -61.0% |
| VRNA | Sell | Verona Pharma Plcsponsored ads | $6,266,000 | -8.8% | 500,883 | -0.4% | 1.38% | -6.5% |
| PACB | New | Pacific Biosciences of California, Inc. | $6,140,000 | – | 1,135,000 | +100.0% | 1.36% | – |
| ACRS | Aclaris Therapeutics, Inc. | $4,536,000 | -27.3% | 312,368 | 0.0% | 1.00% | -25.5% | |
| SGMO | Sangamo Therapeutics, Inc. | $4,502,000 | +19.4% | 265,605 | 0.0% | 0.99% | +22.3% | |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd. | $3,969,000 | -5.0% | 105,706 | 0.0% | 0.88% | -2.7% | |
| WVE | Sell | WAVE Life Sciences Ltd. | $2,500,000 | -12.9% | 50,000 | -33.3% | 0.55% | -10.7% |
| TOCA | Tocagen, Inc. | $2,316,000 | +67.0% | 148,552 | 0.0% | 0.51% | +70.9% | |
| BDSI | Buy | BioDelivery Sciences International, Inc. | $1,763,000 | +2939.7% | 629,656 | +3129.0% | 0.39% | +3141.7% |
| ARDX | Ardelyx Inc. | $567,000 | +17.6% | 130,304 | 0.0% | 0.12% | +20.2% | |
| Exit | Immunomedics, Inc.call | $0 | – | -150,000 | -100.0% | -0.76% | – | |
| Exit | Immunomedics, Inc.put | $0 | – | -150,000 | -100.0% | -0.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 24 | Q3 2021 | 17.6% |
| Acceleron Pharma Inc. | 22 | Q3 2021 | 25.9% |
| CymaBay Therapeutics, Inc. | 20 | Q3 2022 | 17.6% |
| Aerie Pharmaceuticals, Inc. | 18 | Q1 2020 | 33.5% |
| Ascendis Pharma A/S | 17 | Q3 2022 | 47.8% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 27.4% |
| Natera, Inc. | 16 | Q3 2022 | 21.5% |
| Aimmune Therapeutics, Inc. | 16 | Q3 2019 | 8.1% |
| Verona Pharma PLC. | 15 | Q3 2022 | 30.0% |
| WAVE Life Sciences Ltd. | 15 | Q2 2019 | 20.0% |
View Foresite Capital Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 4 | 2021-11-03 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 3 | 2021-02-10 |
View Foresite Capital Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.